Opinion|Videos|January 21, 2025
CAR T and Evolving Treatment Paradigms for Early R/R MM
Panelists discuss the evolution of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM), the factors that inform its use, and how treatment approaches differ for standard-risk vs functional high-risk patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has the use of CAR T evolved for patients with R/R multiple myeloma and what factors inform your practice?
- Where does CAR T fall in your treatment paradigm? How does your approach differ with patients who are standard risk vs functional high risk?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.
Elranatamab improved PFS vs 3 standard regimens in relapsed/refractory multiple myeloma in the phase 3 MagnetisMM-32 trial.
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Advertisement
Advertisement
Trending on OncLive
1
RELATIVITY-1093 Trial Aims to Advance Nivolumab Plus Relatlimab and Chemo in Nonsquamous NSCLC
2
Dostarlimab Monotherapy Elicits Durable cCRs in dMMR/MSI-H Locally Advanced Rectal Cancer
3
NEXERA-303 Trial Aims to Bring TGFβR2×PD-1 Bispecific Antibody INCA33890 Into First-Line MSS CRC
4
The OncFive: Top Oncology Articles for the Week of 10/25
5